close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

71.56 +0.72 (+1.01%)
Delayed Quote Updated: 10:49 AM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ANI Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential ↗
Piper Sandler has initiated coverage on ANI Pharmaceuticals, emphasizing its strategic shift towards high-margin brand assets, particularly the successful Cortrophin Gel, which has seen substantial... 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring ANI Pharmaceuticals Through Analyst Insights ↗
 
Via Benzinga
News headline image
In-Depth Examination Of 4 Analyst Recommendations For ANI Pharmaceuticals ↗
 
Via Benzinga
News headline image
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger
From ANI Pharmaceuticals, Inc. and Alimera Sciences, Inc.
Via Business Wire
News headline image
Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts ↗
 
Via Benzinga
News headline image
Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 29, 2024 ↗
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
News headline image
ANI Pharmaceuticals's Earnings Outlook ↗
 
Via Benzinga
News headline image
ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 ↗
ANIP stock results show that ANI Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Morphic Holding, Inc. (Nasdaq - MORF), Desktop Metal, Inc. (NYSE - DM), Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR), PlayAGS, Incorporated (NYSE - AGS), RBAZ Bancorp, Inc. (OTCPK - RBAZ)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Expert Ratings for ANI Pharmaceuticals ↗
 
Via Benzinga
News headline image
Analyst Expectations for ANI Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Nasdaq Records Worst Session Since April With Nvidia Plunging 7%: Dow Jones Sees Modest Gains Amid Mixed Market Close ↗
 
Via Benzinga
Topics Stocks
News headline image
Why Is Alimera Sciences (ALIM) Stock Up 77% Today? ↗
Alimera Sciences stock is up on Monday as investors react to a $5.50 per share acquisition offer for ALIM from ANI Pharmaceuticals. 
Via InvestorPlace
News headline image
Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal ↗
ANI Pharmaceuticals to acquire Alimera Sciences for $5.50 per share in cash, plus a contingent value right of up to $0.50 per share. The transaction is valued at $381 million and is expected to close... 
Via Benzinga
News headline image
ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 ↗
ANIP stock results show that ANI Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
What 4 Analyst Ratings Have To Say About ANI Pharmaceuticals ↗
 
Via Benzinga
News headline image
Where ANI Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
Looking Into ANI Pharmaceuticals's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Alphabet, Dover And 2 Other Stocks Insiders Are Selling ↗
The Nasdaq 100 closed lower by around 1.5% on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
Drug Maker Organon Stock Scores Relative Strength Upgrade ↗
In a welcome move, drug maker Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday. 
Via Investor's Business Daily
News headline image
Truist Securities Maintains Buy Rating for ANI Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Why Is Generic Drug Player ANI Pharmaceuticals Stock Trading Lower Today? ↗
ANI Pharmaceuticals Inc's (NASDAQ: ANIP) third-quarter revenues were $131.8 million, up 57.3% Y/Y, beating the  
Via Benzinga
ANI Pharmaceuticals Inc. (NASDAQ: ANIP) Records 52-Week High Wednesday Morning
Via Investor Brand Network
News headline image
7 A-Rated Biotech Stocks for Your August Buy List ↗
Investing in biotech stocks means accepting a long R&D window, but the rewards when your A-rated biotech stocks come through are huge. 
Via InvestorPlace
News headline image
ANI Pharmaceuticals to Present at the Jefferies Healthcare Conference
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From ANI Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.